Bayer's Courtroom Countdown: A $7.25 Billion Handshake in Missouri Now Overshadows Pipeline Progress

Monsanto asks a Missouri court to approve a $7.25 billion Roundup settlement, as Bayer shares rise 32% this year on hopes of closing the litigation.

Monsanto has formally asked a Missouri court to sign off on a $7.25 billion settlement, a filing dated September 14 that could finally draw a line under tens of thousands of US lawsuits alleging that its Roundup weedkiller causes cancer. The proposed deal, first reported by Reuters, would run for a maximum of 21 years and pay individual claimants between $10,000 and $165,000 on a tiered scale.

For Bayer, the Leverkusen-based parent that inherited the litigation when it bought Monsanto, the stakes could hardly be higher. The company has said publicly that there is no alternative route to resolving the dispute, and its shares have already begun to price in the possibility of closure. The stock last changed hands at EUR 48.90, up 32% since the start of the year.

That advance sits on a single, sharply defined catalyst. If the judge grants the request, the single largest overhang on Bayer's valuation would shrink dramatically, clearing the way for investors to focus on the operating businesses again. Should the court balk, or should enough plaintiffs reject the terms, the old uncertainty returns in full — and with it the risk of fresh jury awards that make the company's liabilities impossible to size.

A Portfolio Being Reshaped on Two Fronts

While the legal drama plays out, Bayer has been quietly redrawing the map of its pharmaceutical division. Grünenthal has agreed to take over the cancer drug Stivarga, in a deal worth up to EUR 375 million. The transaction sheds an older product just as newer medicines move toward commercialization — part of a deliberate pruning of the portfolio rather than a retreat from oncology.

The pipeline, meanwhile, has been delivering. On September 9, the US Food and Drug Administration granted accelerated approval to sevabertinib, marketed as Hyrnuo, for adults with locally advanced or metastatic non-squamous NSCLC whose tumors carry HER2-TKD activating mutations. It marks a regulatory milestone in America and a fresh addition to Bayer's cancer franchise.

That is not the only green light from Washington. The FDA has also cleared finerenone for chronic kidney disease associated with type 1 diabetes, and roughly a month earlier broadened the label for Kerendia. Two approvals and an expanded indication in short order give the company tangible evidence that its research spending is converting into revenue-generating assets.

Seeds of a Longer-Term Bet in Agriculture

Beyond the courtroom and the clinic, Bayer is placing chips on the farm of the future. Its subsidiary Robigo, together with Leaps by Bayer, announced a Series A financing round aimed at developing genetically engineered biological products designed to protect yields and bring down agricultural costs. It is a long-horizon wager, but one that fits the group's push into next-generation crop protection.

The logic is straightforward: a company freed from the drag of unpredictable litigation can let operational wins translate into share-price gains. A confirmed settlement would not merely remove the threat of further trials — it would refocus attention on pipelines, approvals and field-level innovation.

What Could Still Go Wrong

The optimistic reading is not the only one. US courts scrutinize class settlements of this kind closely, particularly on how they treat future or dissenting claims. Claimants who find the $10,000-to-$165,000 range inadequate may choose to press on outside the agreement, and a meaningful number of holdouts would leave the door open to costly individual suits.

A rejection in Missouri would restore the status quo ante, with the full weight of unknown liabilities pressing back onto the balance sheet and the recent rally called into question. Until the judge rules, the market is effectively trading a binary outcome — and the verdict, not the pipeline, is what will set the tone for Bayer's next chapter.